A Rapidly Progressive Case of Ectopic Adrenocorticotropic Hormone (ACTH) Syndrome.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
03 Nov 2021
03 Nov 2021
Historique:
entrez:
3
11
2021
pubmed:
4
11
2021
medline:
5
11
2021
Statut:
epublish
Résumé
BACKGROUND Adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome (CS) secondary to an ectopic source is an uncommon condition, accounting for 4-5% of all cases of CS. Refractory hypokalemia can be the presenting feature in patients with ectopic ACTH syndrome (EAS), and is seen in up to 80% of cases. EAS can be rapidly progressive and life-threatening without timely diagnosis and intervention. CASE REPORT We present a case of a 74-year-old White woman who first presented with hypokalemia, refractory to treatment with potassium supplementation and spironolactone. She progressively developed generalized weakness, recurrent falls, bleeding peptic ulcer disease, worsening congestive heart failure, and osteoporotic fracture. A laboratory workup showed hypokalemia, hypernatremia, and primary metabolic alkalosis with respiratory acidosis. Hormonal evaluation showed elevated ACTH, DHEA-S, 24-h urinary free cortisol, and unsuppressed cortisol following an 8 mg dexamethasone suppression test, suggestive of ACTH-dependent CS. CT chest, abdomen, and pelvis, and FDG/PET CT scan showed a 1.4 cm right lung nodule and bilateral adrenal enlargement, confirming the diagnosis of EAS, with a 1.4-cm lung nodule being the likely source of ectopic ACTH secretion. Due to the patient's advanced age, comorbid conditions, and inability to attend to further evaluation and treatment, her family decided to pursue palliative and hospice care. CONCLUSIONS This case illustrates that EAS is a challenging condition and requires a multidisciplinary approach in diagnosis and management, which can be very difficult in resource-limited areas. In addition, a delay in diagnosis and management often results in rapid deterioration of clinical status.
Identifiants
pubmed: 34728594
pii: 934437
doi: 10.12659/AJCR.934437
pmc: PMC8574168
doi:
Substances chimiques
Adrenocorticotropic Hormone
9002-60-2
Hydrocortisone
WI4X0X7BPJ
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e934437Références
Case Rep Endocrinol. 2016;2016:8453801
pubmed: 26989527
BMC Endocr Disord. 2015 Nov 26;15:72
pubmed: 26610855
J Clin Endocrinol Metab. 2015 Sep;100(9):3231-44
pubmed: 26158607
Pituitary. 2019 Oct;22(5):445-455
pubmed: 31236798
Ann N Y Acad Sci. 2020 Mar;1463(1):60-66
pubmed: 31456238
Neuroendocrinology. 2010;92 Suppl 1:120-4
pubmed: 20829632
J Nucl Med. 2011 Dec;52(12):1864-70
pubmed: 22072704
Endocr Pract. 2021 Sep;27(9):859-865
pubmed: 33652108
Ann Oncol. 2010 Mar;21(3):548-555
pubmed: 19759190
Clin Endocrinol (Oxf). 2018 Nov;89(5):570-576
pubmed: 30019523
Mol Imaging Radionucl Ther. 2013 Aug;22(2):49-55
pubmed: 24003397
Eur J Endocrinol. 2020 Apr;182(4):R29-R58
pubmed: 31999619
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31665382
Nat Clin Pract Endocrinol Metab. 2008 Dec;4(12):695-700
pubmed: 18941436
Curr Opin Endocrinol Diabetes Obes. 2020 Jun;27(3):146-154
pubmed: 32250975
J Clin Endocrinol Metab. 2006 Oct;91(10):3746-53
pubmed: 16868050
J Clin Endocrinol Metab. 2006 Feb;91(2):371-7
pubmed: 16303835
JAMA. 2011 Dec 28;306(24):2742
pubmed: 22203546
J Clin Endocrinol Metab. 2000 Jan;85(1):42-7
pubmed: 10634361
Mini Rev Med Chem. 2007 May;7(5):467-80
pubmed: 17504182